0001179110-19-000867.txt : 20190123
0001179110-19-000867.hdr.sgml : 20190123
20190123083509
ACCESSION NUMBER: 0001179110-19-000867
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190117
FILED AS OF DATE: 20190123
DATE AS OF CHANGE: 20190123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Knowlton Calvin H
CENTRAL INDEX KEY: 0001685833
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37888
FILM NUMBER: 19536568
MAIL ADDRESS:
STREET 1: 228 STRAWBRIDGE DRIVE
STREET 2: SUITE 100
CITY: MOORESTOWN
STATE: NJ
ZIP: 08057
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tabula Rasa HealthCare, Inc.
CENTRAL INDEX KEY: 0001651561
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389]
IRS NUMBER: 465726437
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 228 STRAWBRIDGE DRIVE
STREET 2: SUITE 100
CITY: MOORESTOWN
STATE: NJ
ZIP: 08057
BUSINESS PHONE: 866-648-2767
MAIL ADDRESS:
STREET 1: 228 STRAWBRIDGE DRIVE
STREET 2: SUITE 100
CITY: MOORESTOWN
STATE: NJ
ZIP: 08057
4
1
edgar.xml
FORM 4 -
X0306
4
2019-01-17
0
0001651561
Tabula Rasa HealthCare, Inc.
TRHC
0001685833
Knowlton Calvin H
228 STRAWBRIDGE DRIVE
SUITE 100
MOORESTOWN
NJ
08057
1
1
0
0
Chief Executive Officer
Common Stock
2019-01-17
4
S
0
2924
63.54
D
775147
I
Held by spouse.
Common Stock
2019-01-17
4
S
0
3396
64.71
D
771751
I
Held by spouse.
Common Stock
2019-01-17
4
S
0
400
65.70
D
771351
I
Held by spouse.
Common Stock
2019-01-17
4
S
0
1080
66.52
D
770271
I
Held by spouse.
Common Stock
2019-01-17
4
S
0
200
67.63
D
770071
I
Held by spouse.
Common Stock
844419
D
Common Stock
10000
I
Held by trust for children.
Common Stock
10000
I
Held by trust for children.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Orsula V. Knowlton on May 15, 2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.12 to $64.10, inclusive. The reporting person undertakes to provide to Tabula Rasa HealthCare, Inc., any security holder of Tabula Rasa HealthCare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.31 to $65.15, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.31 to $66.12, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.37 to $66.92, inclusive.
The sales aggregated in Row 1 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
The sales aggregated in Row 2 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
The sales aggregated in Row 3 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
The sales aggregated in Row 4 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
The sale in Row 5 of Table I is not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
/s/ Brian W. Adams, Attorney-in-fact
2019-01-23